share_log

InMed Pharmaceuticals | 8-K: InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

SEC ·  Feb 13 14:39

Summary by Moomoo AI

InMed Pharmaceuticals reported Q2 FY2025 financial results with a net loss of $2.6M, compared to $1.5M in the previous year. Revenue from BayMedica's commercial operations reached $1.1M, down 10% YoY, though achieving a net income of $0.23M. The company held $3.5M in cash and investments as of December 31, 2024, with an additional $2.9M raised in January 2025.The company made significant progress in its pharmaceutical pipeline. INM-901 demonstrated promising results in Alzheimer's disease treatment, showing reduction in neuroinflammatory markers. For the AMD program, INM-089 achieved a milestone with the selection of an intravitreal formulation as the drug delivery method.Research and development expenses increased to $1M from $0.6M YoY, while general and administrative expenses rose to $1.6M from $1.4M. The company expects current funding to sustain operations through Q2 2025, depending on BayMedica's commercial performance and operating expenses.
InMed Pharmaceuticals reported Q2 FY2025 financial results with a net loss of $2.6M, compared to $1.5M in the previous year. Revenue from BayMedica's commercial operations reached $1.1M, down 10% YoY, though achieving a net income of $0.23M. The company held $3.5M in cash and investments as of December 31, 2024, with an additional $2.9M raised in January 2025.The company made significant progress in its pharmaceutical pipeline. INM-901 demonstrated promising results in Alzheimer's disease treatment, showing reduction in neuroinflammatory markers. For the AMD program, INM-089 achieved a milestone with the selection of an intravitreal formulation as the drug delivery method.Research and development expenses increased to $1M from $0.6M YoY, while general and administrative expenses rose to $1.6M from $1.4M. The company expects current funding to sustain operations through Q2 2025, depending on BayMedica's commercial performance and operating expenses.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 399

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
Cumberland Pharmaceuticals
CPIX
4.410
IM Cannabis
IMCC
1.839
Journey Medical
DERM
6.110
Quantum BioPharma
QNTM
8.560
Citius Oncology
CTOR
0.665
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1546 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....